|
CN103269687A
|
|
Bepotastine compositions
|
|
CN103260623A
|
|
Bepotastine compositions
|
|
CN101965183A
|
|
Eye NSAID as adjuvant
|
|
EP1968646A2
|
|
A predictive tool for hyaluronidase treatment success
|
|
WO2007005856A1
|
|
Use of hyaluronidase in combination with plasmin for the induction of posterior vitreous detachment
|
|
US2006183698A1
|
|
Ophthalmic formulations and uses thereof
|
|
WO2005118799A1
|
|
Ovine hyaluronidase
|
|
WO2004092361A1
|
|
Process for isolating and purifing ovine hyaluronidase
|
|
US7115408B1
|
|
Method of stabilizing hyaluronidase with annexin II
|
|
AU9344901A
|
|
Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
|
|
AU4511201A
|
|
Compositions and methods for the induction and treatment of retinal detachments
|
|
AU5340200A
|
|
Enzymatic method and compositions for treating intravitreal hemorrhagic blood
|
|
AU4672300A
|
|
Biochemical methods that eliminate corneal scars, opacification and haze
|
|
US6610292B2
|
|
Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
|
|
AU3073999A
|
|
Use of corneal hardening agents in enzyme orthokeratology
|
|
AU2476199A
|
|
Methods and apparatus for accelerated orthokeratology
|
|
EP0608341A1
|
|
Enzyme-orthokeratology
|
|
EP1159941A2
|
|
Formulations for use in enzyme-orthokeratology
|
